Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
HUM Humana	$303.90 +2.0%	$254.43	$206.87 ▼ $382.72	$36.52B	0.44	1.40 million shs	1.10 million shs
PFE Pfizer	$24.74 +0.6%	$24.79	$20.92 ▼ $30.43	$140.77B	0.52	43.71 million shs	37.00 million shs
UNH UnitedHealth Group	$309.77 +2.5%	$288.16	$234.60 ▼ $630.73	$280.64B	0.43	20.29 million shs	12.02 million shs
XLV Health Care Select Sector SPDR Fund	$137.43 +0.7%	$134.34	$127.35 ▼ $159.64	$34.07B	0.7	11.41 million shs	9.64 million shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
HUM Humana	0.00%	+1.29%	+21.73%	+30.48%	-13.77%
PFE Pfizer	0.00%	-4.21%	+6.31%	+5.45%	-13.97%
UNH UnitedHealth Group	0.00%	+0.87%	+24.19%	+2.89%	-47.36%
XLV Health Care Select Sector SPDR Fund	0.00%	-0.54%	+5.37%	+3.47%	-11.79%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
HUM Humana	4.1271 of 5 stars	2.2	3.0	2.5	3.9	3.0	1.7	1.3
PFE Pfizer	4.7822 of 5 stars	2.2	3.0	4.2	4.5	2.3	1.7	3.1
UNH UnitedHealth Group	4.942 of 5 stars	3.3	3.0	4.2	4.0	2.8	2.5	2.5
XLV Health Care Select Sector SPDR Fund	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
HUM Humana	2.30	Hold	$283.29	-6.78% Downside
PFE Pfizer	2.39	Hold	$28.12	13.66% Upside
UNH UnitedHealth Group	2.50	Moderate Buy	$353.00	13.95% Upside
XLV Health Care Select Sector SPDR Fund	2.68	Moderate Buy	$137.43	N/A

Current Analyst Ratings Breakdown

Latest XLV, PFE, HUM, and UNH Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/26/2025	UNH UnitedHealth Group	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$440.00
8/21/2025	HUM Humana	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$283.00 ➝ $322.00
8/20/2025	UNH UnitedHealth Group	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$342.00 ➝ $325.00
8/18/2025	UNH UnitedHealth Group	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$290.00 ➝ $325.00
8/14/2025	HUM Humana	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$348.00 ➝ $344.00
8/6/2025	PFE Pfizer	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$25.00 ➝ $26.00
8/6/2025	PFE Pfizer	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$32.00 ➝ $33.00
8/6/2025	PFE Pfizer	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$27.00 ➝ $28.00
8/6/2025	UNH UnitedHealth Group	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$418.00 ➝ $310.00
8/4/2025	UNH UnitedHealth Group	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$306.00 ➝ $267.00
7/31/2025	HUM Humana	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Equal Weight ➝ Equal Weight	$268.00 ➝ $275.00

(Data available from 8/31/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
HUM Humana	$123.11B	0.30	$23.89 per share	12.72	$152.11 per share	2.00
PFE Pfizer	$63.63B	2.21	$4.36 per share	5.67	$15.66 per share	1.58
UNH UnitedHealth Group	$400.28B	0.70	$32.37 per share	9.57	$110.93 per share	2.79
XLV Health Care Select Sector SPDR Fund	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
HUM Humana	$1.21B	$13.03	23.32	23.15	1.79	1.28%	13.67%	4.85%	10/29/2025 (Estimated)
PFE Pfizer	$8.03B	$1.88	13.16	8.16	0.88	16.84%	21.42%	9.12%	11/4/2025 (Estimated)
UNH UnitedHealth Group	$14.41B	$23.08	13.42	9.32	2.00	5.04%	23.32%	7.66%	10/21/2025 (Estimated)
XLV Health Care Select Sector SPDR Fund	N/A	N/A	21.15	∞	N/A	N/A	N/A	N/A	N/A

Latest XLV, PFE, HUM, and UNH Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/5/2025	Q2 2025	PFE Pfizer	$0.58	$0.78	+$0.20	$0.51	$13.43 billion	$14.65 billion
7/30/2025	Q2 2025	HUM Humana	$6.32	$6.27	-$0.05	$4.51	$31.85 billion	$32.39 billion
7/29/2025	Q2 2025	UNH UnitedHealth Group	$4.45	$4.08	-$0.37	$3.74	$111.75 billion	$111.62 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
HUM Humana	$3.54	1.16%	N/A	27.17%	N/A
PFE Pfizer	$1.72	6.95%	N/A	91.49%	16 Years
UNH UnitedHealth Group	$8.84	2.85%	N/A	38.30%	15 Years
XLV Health Care Select Sector SPDR Fund	$2.39	1.74%	N/A	N/A	N/A

Latest XLV, PFE, HUM, and UNH Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
8/21/2025	HUM Humana	quarterly	$0.8850	1.2%	9/26/2025	9/26/2025	10/31/2025
8/13/2025	UNH UnitedHealth Group	quarterly	$2.21	3.38%	9/15/2025	9/15/2025	9/23/2025
6/25/2025	PFE Pfizer	quarterly	$0.43	7.08%	7/25/2025	7/25/2025	9/2/2025
6/5/2025	UNH UnitedHealth Group	quarterly	$2.21	3%	6/16/2025	6/16/2025	6/24/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
HUM Humana	0.69	1.95	1.95
PFE Pfizer	0.65	1.16	0.85
UNH UnitedHealth Group	0.73	0.85	0.85
XLV Health Care Select Sector SPDR Fund	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
HUM Humana	92.38%
PFE Pfizer	68.36%
UNH UnitedHealth Group	87.86%
XLV Health Care Select Sector SPDR Fund	N/A

Insider Ownership

Company	Insider Ownership
HUM Humana	0.37%
PFE Pfizer	0.06%
UNH UnitedHealth Group	0.28%
XLV Health Care Select Sector SPDR Fund	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
HUM Humana	65,680	120.27 million	119.83 million	Optionable
PFE Pfizer	81,000	5.69 billion	5.68 billion	Optionable
UNH UnitedHealth Group	400,000	905.67 million	903.14 million	Optionable
XLV Health Care Select Sector SPDR Fund	N/A	247.91 million	N/A	Not Optionable

XLV, PFE, HUM, and UNH Headlines

Recent News About These Companies

XLV Vs. IHE: Will Pharmaceuticals Outperform Healthcare?

August 28 at 4:01 PM | seekingalpha.com

Healthcare stocks: are they well-positioned to weather Trump tariffs?

August 25, 2025 | invezz.comI

Top 5 ETFs and Stocks to Watch as the Fed Eyes Rate Cuts (XLV)

...

August 25, 2025 | marketbeat.com

Healthcare ETF Discount Highlights Value Ahead of Ozempic Growth Cycle

August 21, 2025 | msn.com

Is This the Right Time to Consider Healthcare ETFs?

August 21, 2025 | zacks.com

Ozempic Boom: Hims & Eli Lilly Lead Healthcare Bets (XLV)

...

August 21, 2025 | marketbeat.com

Should You Invest in the Health Care Select Sector SPDR ETF (XLV)?

August 14, 2025 | zacks.com

THW: Discounted Valuation Due To Higher Interest Rates

August 8, 2025 | seekingalpha.com

Healthcare: Winning Sector ETF Amid Soft U.S. July Jobs Report

August 6, 2025 | zacks.com

Earnings Scorecard: 18 out of 21 healthcare firms beat earnings forecast this week

August 3, 2025 | msn.com

Beyond Broad Healthcare: A Smarter Prescription for Growth

August 1, 2025 | etftrends.comE

12 out of 12 healthcare firms top revenue estimates this week: Earnings Scorecard

July 27, 2025 | msn.com

XLV: Life Expectancy, Patents, And A Positive Outlook Will Pave The Way

July 16, 2025 | seekingalpha.com

SA Quant's top healthcare picks amid Q2 earnings season

July 11, 2025 | msn.com

House Passes Trump's "Big, Beautiful Bill": ETFs in Focus

July 7, 2025 | zacks.com

June Jobs Data Puts Focus on Healthcare ETFs & Stocks

July 7, 2025 | zacks.com

XLV: The S&P 500's Most Discounted Sector? Uncover The Hidden Risk

July 3, 2025 | seekingalpha.com

IDEXX, DexCom lead S&P 500 healthcare gains in Q2; UnitedHealth and Bristol Myers Squibb among top laggards

July 2, 2025 | msn.com

UnitedHealth, CVS Among Major Insurers To Fast-Track Prior Authorizations: Will It Cut Profits Even More?

June 23, 2025 | benzinga.com

Short bets on S&P 500 Healthcare sector ease in May; MRNA stays most shorted stock

June 13, 2025 | msn.com

I've never seen a setup this negative for health care job growth, says Bancreek's Pachman

June 12, 2025 | youtube.comY

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

XLV, PFE, HUM, and UNH Company Descriptions

Humana NYSE:HUM

$303.90 +6.01 (+2.02%)

Closing price 08/29/2025 03:59 PM Eastern

Extended Trading

$304.27 +0.37 (+0.12%)

As of 08/29/2025 07:59 PM Eastern

Humana Inc., together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits. In addition, the company provides commercial fully-insured medical and specialty health insurance benefits comprising dental, vision, life insurance, and other supplemental health benefits, as well as administrative services only products to individuals and employer groups; military services, such as TRICARE T2017 East Region contract; and engages in the operations of pharmacy benefit manager business. Further, it operates pharmacies and senior focused primary care centers; and offers home solutions services, such as home health, hospice, and other services to its health plan members, as well as to third parties. The company sells its products through employers and employees, independent brokers and agents, sales representatives, and digital insurance agencies. The company was formerly known as Extendicare Inc. and changed its name to Humana Inc. in April 1974. Humana Inc. was founded in 1961 and is headquartered in Louisville, Kentucky.

Pfizer NYSE:PFE

$24.74 +0.14 (+0.57%)

Closing price 08/29/2025 03:59 PM Eastern

Extended Trading

$24.78 +0.04 (+0.15%)

As of 08/29/2025 07:59 PM Eastern

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

UnitedHealth Group NYSE:UNH

$309.77 +7.48 (+2.48%)

Closing price 08/29/2025 03:59 PM Eastern

Extended Trading

$308.97 -0.80 (-0.26%)

As of 08/29/2025 08:00 PM Eastern

UnitedHealth Group Incorporated operates as a diversified health care company in the United States. The company operates through four segments: UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx. The UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, and individuals; health care coverage, and health and well-being services to individuals age 50 and older addressing their needs; Medicaid plans, children's health insurance and health care programs; and health and dental benefits, and hospital and clinical services, as well as health care benefits products and services to state programs caring for the economically disadvantaged, medically underserved, and those without the benefit of employer-funded health care coverage. The Optum Health segment provides care delivery, care management, wellness and consumer engagement, and health financial services patients, consumers, care delivery systems, providers, employers, payers, and public-sector entities. The Optum Insight segment offers software and information products, advisory consulting arrangements, and managed services outsourcing contracts to hospital systems, physicians, health plans, governments, life sciences companies, and other organizations. The Optum Rx segment provides pharmacy care services and programs, including retail network contracting, home delivery, specialty and community health pharmacy services, infusion, and purchasing and clinical capabilities, as well as develops programs in the areas of step therapy, formulary management, drug adherence, and disease/drug therapy management. UnitedHealth Group Incorporated was founded in 1974 and is based in Minnetonka, Minnesota.

Health Care Select Sector SPDR Fund NYSEARCA:XLV

$137.43 +1.00 (+0.73%)

Closing price 08/29/2025 04:10 PM Eastern

Extended Trading

$137.54 +0.11 (+0.08%)

As of 08/29/2025 07:56 PM Eastern

Health Care Select Sector SPDR Fund (the Fund) seeks to closely match the returns and characteristics of the S&P Health Care Select Sector Index (the Index). The companies included in the Index are selected on the basis of general industry classification from a universe of companies defined by the Standard & Poor's 500 Composite Stock Index (S&P 500). The Health Care Select Sector Index includes companies from the industries, such as pharmaceuticals, healthcare providers and services, healthcare equipment and supplies, biotechnology, life sciences tools and services, and healthcare technology. Under normal market conditions, the Fund generally invests substantially all, but at least 95%, of its total assets in the securities comprising the Index. State Street Global Advisors acts as the Fund's investment manager.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time